Tag Archives: Akouos

Bio Roundup: Gilead’s Pionyr Grab, Relay to IPO, Unicorn Sana & More

Uncertainty related to the continued spread of the pandemic continued to consume most of the oxygen in the room this week, but life sciences news outside of that arena continued apace. Once considered all but shuttered, the IPO market again saw an active week between new public debuts and more companies joining the queue. Indeed, […]

Posted in Boston blog main, Boulder/Denver blog main, Detroit blog main, Europe blog main, Indiana blog main, National, National blog main, National top stories, New York blog main, Philadelphia Blog Main, Raleigh-Durham blog main, San Diego blog main, San Francisco blog main, Seattle blog main, Texas blog main, Wisconsin blog main | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Bio Roundup: Gilead’s Pionyr Grab, Relay to IPO, Unicorn Sana & More

Biotech Roundup: BIO on Racism, AbbVie Antibodies, IPO Surge & More

At the start of 2020 thousands of biotechies anticipated spending the second week of June in San Diego, hobnobbing at the annual conference hosted by the Biotechnology Innovation Organization. Instead, attendees from 64 countries spanning 28 times zones convened online this week for the first-ever virtual BIO International Convention. There, topics once as unanticipated as the […]

Posted in Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, Europe blog main, Europe top stories, Indiana blog main, Indiana top stories, National, National blog main, National top stories, New York blog main, New York top stories, Philadelphia Blog Main, Philadelphia Top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Texas top stories, Wisconsin blog main, Wisconsin top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Biotech Roundup: BIO on Racism, AbbVie Antibodies, IPO Surge & More

Akouos Aims for an IPO to Advance Hearing Loss Gene Therapy to Clinic

Hearing loss can stem from a variety of reasons, but in rare cases it’s caused by genetic defects. Akouos is developing a gene therapy to address these problems and it’s planning an IPO to finance the first tests of its approach in humans. In paperwork filed with regulators late Friday, Boston-based Akouos set a preliminary […]

Posted in Boston, Boston blog main, Boston top stories, National blog main, National top stories, New York blog main, New York top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories | Tagged , , , , , , , , , , , , , , , , | Comments Off on Akouos Aims for an IPO to Advance Hearing Loss Gene Therapy to Clinic

Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More

Last month, Gilead Sciences CEO Daniel O’Day announced plans to introduce 10 “transformative medicines” over the next 10 years. Acquisitions would help meet that ambitious goal, and this week Gilead announced one of them: a nearly $5 billion deal for cancer immunotherapy developer Forty Seven. Forty Seven’s lead CD47-blocking drug—the company is named after the […]

Posted in Boston blog main, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, Europe blog main, Europe top stories, Indiana blog main, Indiana top stories, National, National blog main, National top stories, New York blog main, New York top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Texas top stories, Wisconsin blog main, Wisconsin top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More

Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds

Hearing loss affects millions of Americans but to date, there are no FDA-approved medicines to treat them. Frequency Therapeutics is developing a hearing loss drug that taps into the body’s regenerative capabilities. As the company prepares to advance the experimental treatment to mid-stage studies, it is planning an IPO to finance the research. Frequency set […]

Posted in Boston, Boston blog main, National blog main, San Francisco blog main | Tagged , , , , , , , , , , , , , , , , , , , , , | Comments Off on Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds

Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone

Being first to market with a new type of drug brings advantages. The first mover sets the bar for what physicians, payers, and patients can expect of that medicine and how much it costs. It grabs market share that followers have to steal away. But the first mover isn’t infallible if someone else has something […]

Posted in Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, Indiana blog main, Indiana top stories, National, National blog main, National top stories, New York blog main, New York top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Texas top stories, Wisconsin blog main, Wisconsin top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone

Frequency Nabs $42M for Hearing Loss Drugs, Clinical Data On The Way

Hearing loss drug development continues to attract investment, with Frequency Therapeutics announcing today that it has brought in $42 million in a Series B financing to help it move its treatment through clinical testing. Boston area-based Frequency is working on small molecule drugs that stimulate the growth of dormant stem cells in the body, and […]

Posted in Boston, Boston blog main, Boston top stories, National blog main | Tagged , , , , , , , , , , | Comments Off on Frequency Nabs $42M for Hearing Loss Drugs, Clinical Data On The Way

Now Hear This: Akouos Secures $50M for Hearing Loss Gene Therapy R&D

Hearing loss for many people is hereditary—a mutation in a single gene impairs hearing from birth. There are no approved drugs for this type of hearing loss, but biotech startup Akouos is developing a gene therapy to help patients recover the ability to hear. Boston-based Akouos says it has secured a $50 million financial commitment […]

Posted in Boston, Boston blog main, Boston top stories, National blog main, National top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Now Hear This: Akouos Secures $50M for Hearing Loss Gene Therapy R&D